Showing results (91-100 of 201) with videos related to
Sort By:
Pageof 21
Gynecologic Oncology|July 7, 2023
A phase 2 study of dasatinib in recurrent clear cell carcinoma of the ovary, fallopian tube, peritoneum or endometrium: NRG oncology/gynecologic oncology group study 0283Roisin E O'Cearbhaill, Austin Miller, Robert A Soslow, et al.Life Science Alliance|October 27, 2023
APR-246 increases tumor antigenicity independent of p53Judith Michels, Divya Venkatesh, Cailian Liu, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|July 18, 2022
Microsatellite Instability-High Endometrial Cancers with MLH1 Promoter Hypermethylation Have Distinct Molecular and Clinical ProfilesBeryl L Manning-Geist, Ying L Liu, Kelly A Devereaux, et al.Journal of Surgical Oncology|December 15, 2023
Moving into the modern era of molecular classification for endometrial cancerChristian Dagher, Ying L Liu, Jennifer J Mueller, et al.Gynecologic Oncology|January 22, 2020
A phase 1 dose-escalation study of intraperitoneal cisplatin, intravenous/intraperitoneal paclitaxel, bevacizumab, and olaparib for newly diagnosed ovarian cancerKaren A Cadoo, Rachel N Grisham, Roisin E O'Cearbhaill, et al.Journal for Immunotherapy of Cancer|October 2, 2020
Phase II study of atezolizumab in combination with bevacizumab in patients with advanced cervical cancerClaire F Friedman, Alexandra Snyder Charen, Qin Zhou, et al.Gynecologic Oncology|December 2, 2023
Pathogenic germline variants in non-BRCA1/2 homologous recombination genes in ovarian cancer: Analysis of tumor phenotype and survivalRyan M Kahn, Pier Selenica, Thomas Boerner, et al.The Surgical Clinics of North America|July 8, 2026
Role of Genetics in Gynecologic MalignanciesCorbyn M Nchako, Kara C Long, Ying L Liu, et al.Journal for Immunotherapy of Cancer|November 17, 2024
Phase I study of a recombinant attenuated oncolytic virus, MEDI5395 (NDV-GM-CSF), administered systemically in combination with durvalumab in patients with advanced solid tumorsDiwakar Davar, Benedito A Carneiro, Grace K Dy, et al.Cancers|March 11, 2023
Phase I Study of a Multivalent WT1 Peptide Vaccine (Galinpepimut-S) in Combination with Nivolumab in Patients with WT1-Expressing Ovarian Cancer in Second or Third RemissionBeryl L Manning-Geist, Sacha Gnjatic, Carol Aghajanian, et al.Pageof 21